3-(4-ETHYLPIPERAZIN-1-YL)PROPYL 2,2-DIPHENYLPROPANOATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JZPDHWUJKMRPBA-UHFFFAOYSA-N
Smiles	CCN1CCN(CCCOC(=O)C(C)(c2ccccc2)c3ccccc3)CC1
InChI	InChI=1S/C24H32N2O2/c1-3-25-16-18-26(19-17-25)15-10-20-28-23(27)24(2,21-11-6-4-7-12-21)22-13-8-5-9-14-22/h4-9,11-14H,3,10,15-20H2,1-2H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H32N2O2
Molecular Weight	380.52
AlogP	4.14
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	9.0
Polar Surface Area	32.78
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	28.0

Assay Description	Organism	Bioactivity
Insecticidal activity against fourth-instar larval stage of Bombyx mori Shunrei x Shongetsu assessed as delay in increase of hemolymph 20-hydroxyecdysone level at 50 ppm administered through artificial diet measured for 5 days post third ecdysis by ELISA relative to acetone-treated control	Bombyx mori	None
Insecticidal activity against fourth-instar larval stage of Bombyx mori Shunrei x Shongetsu assessed as fourth-instar larval duration time at 100 ppm administered through artificial diet (Rvb = 5.1 +/- 0.2 days)	Bombyx mori	7.2 day
Insecticidal activity against fourth-instar larval stage of Bombyx mori Shunrei x Shongetsu assessed as fourth-instar larval duration time at 30 ppm administered through artificial diet (Rvb = 5.1 +/- 0.2 days)	Bombyx mori	6.5 day

Cross References

Resources	Reference
ChEMBL	CHEMBL2269540

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).